# A Study to Evaluate the Efficacy and Safety of Tanfanercept (HL036) in Dry Eye Disease

> **NCT06400589** · PHASE3 · SUSPENDED · sponsor: **HanAll BioPharma Co., Ltd.** · enrollment: 750 (estimated)

## Conditions studied

- Dry Eye

## Interventions

- **DRUG:** tanfanercept
- **DRUG:** Vehicle

## Key facts

- **NCT ID:** NCT06400589
- **Lead sponsor:** HanAll BioPharma Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** SUSPENDED
- **Start date:** 2024-05-01
- **Primary completion:** 2025-08
- **Final completion:** 2025-08
- **Target enrollment:** 750 (ESTIMATED)
- **Why stopped:** Logistical issue
- **Last updated:** 2024-05-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06400589

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06400589, "A Study to Evaluate the Efficacy and Safety of Tanfanercept (HL036) in Dry Eye Disease". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06400589. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*